FOLD News and Press, Amicus Therapeutics Inc. From 10/08/21

Recording the biggest intraday loss in nearly six months, Intellia Therapeutics (NTLA -10.7%) has shed all the gains made since late June when the company and its partner Regeneron (NASDAQ:REGN) showed promising in-vivo CRISPR-based genome editing data for the first time in humans. The w...

Amicus Therapeutics announced the formation of Caritas Therapeutics, consisting of Amicus' gene therapy portfolio. Amicus' stake will go from 100% to 36%, reducing the upside optionality of the gene therapy portfolio. The upside of the deal for Amicus is reduced costs and a clear ...

Merck acquires Acceleron for $180 per share in cash. Amicus Therapeutics to launch a genetic medicine company, Caritas Therapeutics through a business combination agreement with ARYA Sciences Acquisition Corp IV. Five9 and Zoom Video Communications mutually terminate their merger ...

Superior Drilling Products (NYSE:SDPI) +46%. Camber Energy (NYSE:CEI) +16%. Aemetis (NASDAQ:AMTX) +22% signs offtake agreement with Delta Air Lines for 250 million gallons of sustainable aviation fuel Onion Global (NYSE:OG) +17% to launch the "LUCA Elite Club" events in its KOC Comm...

Amicus Therapeutics, Inc. (FOLD) Formation of Caritas Therapeutics Conference Call September 29, 2021, 08:00 AM ET Company Participants Andrew Faughnan - Executive Director, IR John F. Crowley - Chairman and CEO Bradley L. Campbell - President and COO Daphne Quimi - CFO Conference Call Partic...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this event. For further details see: Amicus Caritas Investor Deck FINAL

Applied UV (NASDAQ:AUVI) +41% on KES Science & Technology assets acquisition GeoVax Labs (NASDAQ:GOVX) +24% after deal for clinical-stage cancer program NuCana (NASDAQ:NCNA) +15% receives fast track designation from the U.S. Food and Drug Administration for Acelar...

Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Global Commercia...

FDA Sets PDUFA Target Action Date of May 29, 2022 for the New Drug Application and July 29, 2022 for the Biologics License Application On Track for MAA Submission in the Fourth Quarter of this Year PHILADELPHIA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Amicus Thera...

PHILADELPHIA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 26th International Annual Congress of the World Muscle Society (WMS) being held virtually, ...